Eledon Pharmaceuticals Inc. has announced that it will host a Research and Development Day in New York City on July 9, 2025. The event will focus on Eledon's lead investigational candidate, tegoprubart, particularly its clinical development in organ and cell transplantation. The event will feature members of Eledon's executive team and several leading experts in transplantation, who will discuss topics such as the ongoing Phase 2 BESTOW trial and unmet needs in solid organ transplantation. Additional sessions will address the evolution of clinical endpoints and strategic opportunities in islet cell transplantation and xenotransplantation. The program will conclude with a live Q&A session. Presentation materials and a live webcast of the event will be accessible on the company's website. Results from the studies will be presented during the event.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。